CLINICAL DRUG SUBSTANCE SUPPLY AGREEMENTClinical Drug Substance Supply Agreement • December 4th, 2008 • Facet Biotech Corp • Pharmaceutical preparations • New York
THIS CLINICAL DRUG SUBSTANCE SUPPLY AGREEMENT (this “Agreement”) is effective as of the Effective Date (as defined below) and is by and between GMN, Inc., a Delaware corporation and a wholly owned subsidiary of Genmab A/S, a corporation organized under the laws of Denmark, having its principal place of business at 9450 Winnetka Avenue N, Brooklyn Park, MN (“GMN”) and PDL BioPharma, Inc., a corporation organized under the laws of Delaware, having its principal place of business at 1400 Seaport Boulevard, Redwood City, CA 94063 (“PDL”).
CONFIDENTIAL PROVISIONS REDACTED AMENDMENT NO. 2 TO CLINICAL DRUG SUBSTANCE SUPPLY AGREEMENTClinical Drug Substance Supply Agreement • November 3rd, 2009 • Facet Biotech Corp • Pharmaceutical preparations
THIS AMENDMENT NO. 2 TO CLINICAL DRUG SUBSTANCE SUPPLY AGREEMENT (this “Amendment”) is entered into with effect as of 25 September 2009 (the “Amendment Effective Date”) by and between Genmab MN, Inc. (“Genmab”) and Facet Biotech Corporation (“Facet”) (Genmab and Facet hereinafter together referred to as the “Parties”).
